K50 K51 K52
Conditions
Interventions
Group 1: Children and adolescents with inflammatory bowel disease who receive medical or dietary treatments according to published guidelines. Regular clinical characterisation will be complemented wi
Sponsors
Abteilung für pädiatrische Gastroenterologie und Hepatologie
Dr. von Haunersches Kinderspital
Klinikum der Universität München
Eligibility
Sex/Gender
All
Age
3 Years to 20 Years
Inclusion criteria
Inclusion criteria: Patients with suspicion of IBD or established IBD who receive treatment with exclusive enteral nutrition, steroids, aminosalicylates, immunosuppressive medications (e.g. azathioprine, methotrexate), antibiotics or biologics.
Exclusion criteria
Exclusion criteria: Patients without confirmed IBD after full diagnostic work-up will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prospective analysis of microbial signatures and their functional role for immuneregulation, treatment and clinical course of pediatric IBD patients over two years. | — |
Secondary
| Measure | Time frame |
|---|---|
| Prospective study with 2 years follow-up: - Analysis of environmental factors (nutrition and life-style) for microbiom composition and function in pediatric IBD. - Analysis of interactions between host genetics and microbiome. - Indentification of biomarkers for personalized treatments of pediatric IBD. - Long-term development of microbiom-targeting treatments in pediatric IBD. | — |
Countries
Germany
Contacts
Public ContactTobias Schwerd
Klinikum der Universität München, Dr. von Haunersches Kinderspital; Abteilung für pädiatrische Gastroenterologie und Hepatologie
Outcome results
None listed